These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19663444)

  • 1. A multivalent approach to the design and discovery of orally efficacious 5-HT4 receptor agonists.
    McKinnell RM; Armstrong SR; Beattie DT; Choi SK; Fatheree PR; Gendron RA; Goldblum A; Humphrey PP; Long DD; Marquess DG; Shaw JP; Smith JA; Turner SD; Vickery RG
    J Med Chem; 2009 Sep; 52(17):5330-43. PubMed ID: 19663444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo pharmacological characterization of PF-01354082, a novel partial agonist selective for the 5-HT(4) receptor.
    Mikami T; Komada T; Sugimoto H; Suzuki K; Ohmi T; Kimura N; Naganeo R; Nakata E; Nakatani K; Toga T; Eda H; Sakakibara M
    Eur J Pharmacol; 2009 May; 609(1-3):5-12. PubMed ID: 19285067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.
    Long DD; Armstrong SR; Beattie DT; Choi SK; Fatheree PR; Gendron RA; Goldblum AA; Humphrey PP; Marquess DG; Shaw JP; Smith JA; Derek Turner S; Vickery RG
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4849-53. PubMed ID: 22683222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT4 receptor agonists: similar but not the same.
    De Maeyer JH; Lefebvre RA; Schuurkes JA
    Neurogastroenterol Motil; 2008 Feb; 20(2):99-112. PubMed ID: 18199093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.
    Long DD; Armstrong SR; Beattie DT; Choi SK; Fatheree PR; Gendron RA; Genov D; Goldblum AA; Humphrey PP; Jiang L; Marquess DG; Shaw JP; Smith JA; Turner SD; Vickery RG
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6048-52. PubMed ID: 22959244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.
    Manabe N; Wong BS; Camilleri M
    Expert Opin Investig Drugs; 2010 Jun; 19(6):765-75. PubMed ID: 20408739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-alpha]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in conscious dogs.
    Mikami T; Ochi Y; Suzuki K; Saito T; Sugie Y; Sakakibara M
    J Pharmacol Exp Ther; 2008 Apr; 325(1):190-9. PubMed ID: 18198343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.
    McKinnell RM; Armstrong SR; Beattie DT; Fatheree PR; Long DD; Marquess DG; Shaw JP; Vickery RG
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4210-5. PubMed ID: 23756062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating 5-HT receptor pharmacology.
    Sanger GJ
    Neurogastroenterol Motil; 2009 Dec; 21(12):1235-8. PubMed ID: 19906028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of DA-6886, a novel 5-HT4 receptor agonist to accelerate colonic motor activity in mice.
    Lee MJ; Cho KH; Park HM; Sung HJ; Choi S; Im W
    Eur J Pharmacol; 2014 Jul; 735():115-22. PubMed ID: 24769304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and pharmacological evaluation of benzamide derivatives as selective 5-HT(4) receptor agonists.
    Sonda S; Kawahara T; Katayama K; Sato N; Asano K
    Bioorg Med Chem; 2005 May; 13(9):3295-308. PubMed ID: 15809165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of a pharmacophore model for 5-HT4 agonists using CoMFA and receptor based alignment.
    Iskander MN; Leung LM; Buley T; Ayad F; Di Iulio J; Tan YY; Coupar IM
    Eur J Med Chem; 2006 Jan; 41(1):16-26. PubMed ID: 16293350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of serotonin in the pathophysiology of the irritable bowel syndrome].
    Moskwa A; Boznańska P
    Wiad Lek; 2007; 60(7-8):371-6. PubMed ID: 18175558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents.
    Tian X; Switzer AG; Derose SA; Mishra RK; Solinsky MG; Mumin RN; Ebetino FH; Jayasinghe LR; Webster ME; Colson AO; Crossdoersen D; Pinney BB; Farmer JA; Dowty ME; Obringer CM; Cruze CA; Burklow ML; Suchanek PM; Dong L; Dirr MK; Sheldon RJ; Wos JA
    J Med Chem; 2008 Oct; 51(19):6055-66. PubMed ID: 18771254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological characterization and determination of pharmacokinetic and pharmacodynamic relationship of PF-00885706, a novel partial agonist selective for the 5-HT(4) receptor.
    Komada T; Matsuura T; Mikami T; Suzuki K; Sugimoto H; Kimura N; Ohmi T; Toga T; Nakai Y; Eda H; Sakakibara M
    Pharmacol Res; 2009 Oct; 60(4):237-46. PubMed ID: 19717010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation.
    Miller KJ; Wu GY; Varnes JG; Levesque P; Li J; Li D; Robl JA; Rossi KA; Wacker DA
    Mol Pharmacol; 2009 Dec; 76(6):1211-9. PubMed ID: 19767451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally active benzoxazole derivative as 5-HT3 receptor partial agonist for treatment of diarrhea-predominant irritable bowel syndrome.
    Yoshida S; Shiokawa S; Kawano K; Ito T; Murakami H; Suzuki H; Sato Y
    J Med Chem; 2005 Nov; 48(22):7075-9. PubMed ID: 16250667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease.
    Russo O; Cachard-Chastel M; Rivière C; Giner M; Soulier JL; Berthouze M; Richard T; Monti JP; Sicsic S; Lezoualc'h F; Berque-Bestel I
    J Med Chem; 2009 Apr; 52(8):2214-25. PubMed ID: 19334715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergy between 5-HT4 receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach.
    Cellek S; Thangiah R; Jarvie EM; Vivekanandan S; Lalude O; Sanger GJ
    Neurogastroenterol Motil; 2008 May; 20(5):539-45. PubMed ID: 18194150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.